Ultragenyx Announces Additional Positive Multi-Year Durability Data from Phase 1/2 AAV Gene Therapy Studies
November 29, 2021 08:00 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for...